Breaking Update
Israeli AI Startup Converge Bio Raises $25M to Transform Drug Discovery
Israeli AI startup Converge Bio secures $25 million Series A funding, bringing total to $30M for its AI drug discovery platform.
Jerusalem, 13 January, 2026 (TPS-IL) — Israeli startup Converge Bio has secured $25 million in a Series A round led by Bessemer Venture Partners, bringing its total funding to $30 million. Founded in 2024, Converge develops an AI platform that accelerates drug discovery for Biotech and Pharmaceutical Companies, offering tools for target identification, antibody design, and protein optimization.
The platform is already in use by over a dozen global companies, delivering measurable results in oncology, autoimmune, and neurodegenerative research. CEO Dov Gertz said the goal is to make “every Biotech and pharma company an AI company.”
